|
2014 SPONSOR |
Sanofi Korea has established foundation for solidifying its position as a comprehensive healthcare leader that satisfies diversified needs of patients and consumers in Korea through business strategies of comprising broad areas of prevention,treatment, and consumer healthcare.
Booth No. E028
Exhibition Item
Plavix is the key medical necessity in antiplatelet treatment to prevent atherothrombotic events for patients with ACS, Stroke, PAD and A-fib |
|
The Latest Perspectives on Clinical Benefits and Limitations of Antiplatelet Treatment |
Organized by CVRF and Supported by Educational Grant from SANOFI Korea |
Wednesday, April 23
12:45 PM - 1:45 PM
Room 2-1, Level 2 |
Moderator(s): Hyeon-Cheol Gwon | Panelist(s): Youngkeun Ahn, Jang-Whan Bae, Kwang Soo Cha, Kook-Jin Chun, Joo-Yong Hahn, Jung-Sun Kim, Sung Uk Kwon, Han Cheol Lee, Sang Gon Lee, Seung-Jin Oh, Yongwhi Park | |
12:45 PM |
Opening Remark
Speaker : Hyeon-Cheol Gwon
|
12:48 PM |
Review the Benefits and Limitations of Current Antiplatelet Therapy
Lecturer : Seung-Jin Oh
|
1:03 PM |
Debate on Duration of Antiplatelet Therapy After PCI
Lecturer : Joo-Yong Hahn
|
1:18 PM |
Advances in Atherothrombosis Management in the Complex Patients
Lecturer : Jung-Sun Kim
|
1:33 PM |
Panel Discussion and Closing
Speaker : Hyeon-Cheol Gwon
|
|
|
|
|
|
|
|
|
|
CardioVascular Research Foundation(CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea
Tel: 82-2-3010-7255/ Business registration number: 215-82-06387
Copyright ¨Ï 2002 CVRF, Seoul, Korea. All rights reserved. |
|
|
|